HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shaw, J. E Search for Related Content PubMed Articles by Shaw, J. E

Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in people at risk

Key Words: adenoma • aspirin • colorectal neoplasms • adenoma • aspirin • colorectal neoplasms

The first 150 words of the full text of this article appear below.

Design
Randomised {allocation concealed^*}, blinded (clinicians and patients),^* placebo controlled trial with a mean follow up of 33 months.

Setting
9 clinical centres in Canada and the US.

Patients
1121 patients (mean age 57 y, 64% men) who had 1 of the following: 1 histologically confirmed colorectal adenoma removed <3 months before recruitment; 1 histologically confirmed adenoma removed 16 months before recruitment and a lifetime history of 2 confirmed adenomas; or a histologically confirmed adenoma 1 cm in diameter removed <16 months before recruitment. Exclusion criteria included a history of a familial colorectal cancer syndrome, invasive colorectal cancer, and malabsorption syndromes. Follow up was 97%.

Intervention
Patients were allocated to aspirin, 325 mg/day (n=372) or 81 mg/day (n=377), or placebo (n=372).

Main outcome measure
Number of patients in whom 1 colorectal adenoma was detected at 1 year of follow up.

Main results
At 1 year, 1 colorectal adenoma was detected in fewer patients who received aspirin, 81 . . . [Full text of this article]

James E Shaw, MD, MPH

Virginia Commonwealth University Health System, Richmond, Virginia, USA